ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.94 USD
+0.01 (0.34%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $2.95 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.94 USD
+0.01 (0.34%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $2.95 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Zacks News
Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ADC Therapeutics SA (ADCT) Upgraded to Buy: Here's Why
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?
by Zacks Equity Research
ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
by Zacks Equity Research
Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.